BioCentury | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

...endpoint Kura Oncology Inc. (NASDAQ:KURA) said four patients with relapsed or refractory urothelial cancer receiving tipifarnib...
...peptide-1 receptor; JAK - Janus kinase Sandi Wong and Hongjiang Li, Staff Writers Aerucin (AR-105) CTP-543 PB-718 selatogrel (ACT-246475) tipifarnib (zarnestra, R115777) Aridis...
BioCentury | Jun 19, 2019
Financial News

June 19 Financial Quick Takes: Stoke rises after IPO; plus Polaris, Woodford, follow-ons

...at $17. The fund-raising comes days after newly updated data showed that Kura's lead candidate, tipifarnib...
BioCentury | Jun 29, 2018
Financial News

Kura, Zafgen price follow-ons

...the offering after hours. The company gained $0.25 to $17.30 June 28. Kura’s lead candidate, tipifarnib...
...or metastatic HRAS-mutant SCCHN, which it believes could be registrational based on discussions with regulators. Tipifarnib...
...Kura Oncology Inc. (NASDAQ:KURA), San Diego, Calif. Zafgen Inc. (NASDAQ:ZFGN), Boston, Mass. Jaime De Leon tipifarnib (zarnestra, R115777) ZGN-1061 Kura...
BioCentury | Jun 28, 2018
Financial News

Kura, Zafgen price follow-ons

...proposed the offering after hours. The company gained $0.25 to $17.30 Thursday. Kura’s lead candidate, tipifarnib...
...or metastatic HRAS-mutant SCCHN, which it believes could be registrational based on discussions with regulators. Tipifarnib...
...early next year. ZGN-1061 is a second-generation methionine aminopeptidase 2 (MetAP2) inhibitor. Jaime De Leon tipifarnib (zarnestra, R115777) ZGN-1061 Kura...
BioCentury | May 9, 2018
Distillery Therapeutics

Cancer

...human colorectal cancer cell line treated with alphavirus M1, co-treatment with the farnesyl transferase inhibitor tipifarnib...
...tipifarnib had no effect on viral replication. In human colorectal and pancreatic cancer cell lines, tipifarnib...
...additional models of colorectal and pancreatic cancers. Johnson & Johnson and Kura Oncology Inc. have tipifarnib...
BioCentury | Feb 16, 2018
Clinical News

Kura reports additional Phase II data for tipifarnib in SCCHN

...cell carcinoma of the head and neck (SCCHN) in a Phase II trial showing that tipifarnib...
...Phase III trial of tipifarnib to treat HRAS-mutant SCCHN this year. In September, Kura said tipifarnib...
...protocol required at least four confirmed partial responses out of 18 patients. At the time, tipifarnib...
BioCentury | Feb 2, 2018
Financial News

Kura raises $59.1M in an at-the-market financing

...patients with wild-type RAS chronic myelomonocytic leukemia (CMML) in a Phase II trial showing that tipifarnib...
...NYSE:JNJ) (see BioCentury, March 16, 2015 ). Kura Oncology Inc. (NASDAQ:KURA), La Jolla, Calif. Elizabeth S. Eaton tipifarnib Kura...
BioCentury | Jan 5, 2018
Clinical News

Kura reports Phase II data for tipifarnib in CMML

...seven evaluable patients with mutant RAS CMML, tipifarnib led to 6 cases of stable disease. Tipifarnib...
...This year, the company plans to begin a registration-enabling study of tipifarnib for HRAS-mutant SCCHN. Tipifarnib...
...Inc. (NASDAQ:KURA), La Jolla, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tipifarnib (formerly Zarnestra...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...that back and more not quite a month later when it reported that lead asset tipifarnib...
BioCentury | Sep 15, 2017
Clinical News

Kura's tipifarnib meets in Phase II for SCCHN

...Kura Oncology Inc. (NASDAQ:KURA) said tipifarnib met the primary endpoint in a Phase II trial to...
...available options to advance the development of tipifarnib for HRAS-mutant SCCHN "as quickly as possible.” Tipifarnib...
...Inc. (NASDAQ:KURA), La Jolla, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tipifarnib (formerly Zarnestra...
Items per page:
1 - 10 of 55